Limited benefit of antiretroviral resistance testing in treatment-experienced patients: A meta-analysis

AIDS

Volumn 18, Issue 16, 2004, Pages 2153-2161

  Panidou, Ermioni T ^a   Trikalinos, Thomas A ^a,b   Ioannidis, John P A ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Antiretroviral treatment; Genotypic resistance testing; HIV; Phenotypic resistance testing

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CLINICAL TRIAL; EMBASE; FOLLOW UP; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MEDICAL DECISION MAKING; MEDLINE; META ANALYSIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; T LYMPHOCYTE; TREATMENT PLANNING; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; PHENOTYPE; RANDOMIZED CONTROLLED TRIALS; VIRAL LOAD;

EID: 7744231500     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200411050-00007     Document Type: Article

References (29)

1. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003, 37:113-128.
2. No authors listed. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003, 17(Suppl 2):S3-S26.
3. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.
4. Salama C, Policar M, Cervera C. Knowledge of genotypic resistance mutations among providers of care to patients with human immunodeficiency virus. Clin Infect Dis 2003, 36:101-104.
5. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004, 38:723-730.
6. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 2003, 326:472.
7. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691.
8. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127:820-826.
9. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
10. Pettiti D. Meta-analysis, Decision Analysis, and Cost-Effectiveness Analysis. Oxford: Oxford University Press; 1994.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
12. Egger M, Davey Smith G, Schneider M, Minder C Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997, 315:629-634.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
14. Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, et al. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS 2002, 16:1131-1138.
15. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000, 14:F83-93.
16. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002, 16:369-379.
17. Durant J, Clevenbergh P, Halfen P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353:2195-2199.
18. Durant J, Clevenbergh P, Garraffo R, Halfen P, Icard S, Del Giudice P, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000, 14:1333-1339.
19. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002, 16:579-588.
20. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002, 16:727-736.
21. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002, 16:209-218.
22. Perez-Elias MJ, Garcia-Arota I, Munoz V, Santos I, Sanz J, Abraira V, et al. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antivir Ther 2003, 8:577-584.
23. Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr 2003, 32:268-280.
24. Melnick D, Rosenthal J, Cameron M, Snyder M, Griffith-Howard S, Hertogs K, et al. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2000 [abstract 786].
25. Haubrich RH, Keiser P, Kemper C, Witt M, Leedom J, Forthol D, et al. CCTG 575: A randomized, prospective study of phenotype testing (PHENO) versus standard of care (SOC) for patients failing antiretroviral therapy (ARV). First International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, 2001 [abstract 127].
26. Torre D, Tambini R. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials 2002, 3:1-8.
27. Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-analysis in Context, 2nd edn. London: BMJ Publishing; 2001.
28. Chaix C, Grenier-Sennelier C, Clevenbergh P, Durant J, Schapiro JM, Dellamonica P, et al. Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. J Acquir Immune Defic Syndr 2000, 24:227-231.
29. Kent DM, McGrath D, Ioannidis JP, Bennish ML. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin Infect Dis 2003, 37:S13-S24.